Zobrazeno 1 - 10
of 98
pro vyhledávání: '"L. Dal Lago"'
Autor:
Jwm Martens, Oliver Bogler, Stéphanie Peeters, C. P. Schroder, EP Winer, Isabel T. Rubio, Barbro Linderholm, Larissa A. Korde, Judith Fraser, C.H.M. van Deurzen, Aleksandra Peric, Ingrid Hedenfalk, C. Poncet, Lavinia P. Middleton, Fatima Cardoso, Carrie Cunningham, Catherine M. Kelly, Joanna Vermeij, Peggy L. Porter, Melissa Murray, Sharon H. Giordano, L. Dal Lago, Cecilia Nilsson, M Nowaczyk, CQ Yao, Monika Sobol, Stefan Aebi, E van Leeuwen-Stok, D van den Weyngaert, T Piper, Jms Bartlett, Kathryn J. Ruddy, Kim Benstead, FH Hilbers, Jane Bayani, C. J. van Asperen, N Anouk, Paul C. Boutros, Cheryl Crozier
Publikováno v:
Cancer Research. 79:P6-19
Introduction: Male breast cancer (MBC) is a rare disease accounting for less than 1% of all breast cancers (BC) and 1% of all cancers in males. The clinical management is largely extrapolated from female BC. Several multigene assays are increasingly
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::faed4d8eae31f535255b8f19b4ade3bc
https://doi.org/10.1158/1538-7445.sabcs18-p6-19-01
https://doi.org/10.1158/1538-7445.sabcs18-p6-19-01
Autor:
Q. Wu, B. Brouwers, B.S. Dalmasso, C. Kenis, L. Dal Lago, P. Neven, P. Vuylsteke, G. Debrock, H.F.M. van den Bulck, A. Smeets, A. Laenen, H. Wildiers, S. Hatse
Publikováno v:
Annals of Oncology. 33:S141
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7f2197d17a9d0633d843f4b3d069c158
https://doi.org/10.1016/j.annonc.2022.03.058
https://doi.org/10.1016/j.annonc.2022.03.058
Autor:
Ann Smeets, H. Van den Bulck, Barbara Brouwers, U Wedding, G Debrock, L. Dal Lago, Peter Vuylsteke, Annemarie Coolbrandt, Marije E. Hamaker, Chantal Quinten, A. Bottomley, Patrick Schöffski, Hans Wildiers, Patrick Neven, Cindy Kenis
Publikováno v:
Journal of Geriatric Oncology. 9:152-162
We aim to assess short and long term effects of chemotherapy on patient-reported quality of life (QOL) and patient versus clinician symptom reporting in older patients with breast cancer adjusted for tumour and aging parameters.In this prospective, m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2deaefb101c2058570d2095ee663b682
https://doi.org/10.1016/j.jgo.2017.10.001
https://doi.org/10.1016/j.jgo.2017.10.001
Autor:
Jwm Martens, L Middleton, Konstantinos Tryfonidis, E Winer, Kim Benstead, Joanna Vermeij, Peggy L. Porter, Cecilia Nilsson, M Nowaczyk, Sharon H. Giordano, T Goulioti, Judith Fraser, L Slaets, Anieta M. Sieuwerts, Melissa Murray, V de Weerd, Chm van Deurzen, T Piper, L. Dal Lago, E van Leeuwen-Stok, IT Rubio, Barbro Linderholm, Jms Bartlett, C Ponchet, O Bogler, D van den Weyngaert, C Kelly, W Kloosterman, Clifford A. Hudis, Fatima Cardoso, J Bayani, C. P. Schroder, S Aebi, Marcel Smid, Ingrid Hedenfalk, Stéphanie Peeters, C. J. van Asperen, K Ruddy, C Stangle, L Korde
Publikováno v:
Cancer Research. 78:PD7-12
Introduction. Male breast cancer (male BC) is a rare disease for which disease management is extrapolated from females. IMBC, an international consortium, which previously reported on clinico-pathological aspects, now reports on molecular subgroups r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::925c03c8bed0e11e3d946c1338b47c6e
https://doi.org/10.1158/1538-7445.sabcs17-pd7-12
https://doi.org/10.1158/1538-7445.sabcs17-pd7-12
Autor:
S Waters, E. Brain, L. Dal Lago, Nathan Touati, Fatima Cardoso, Bart Meulemans, Barbara Brouwers, Konstantinos Tryfonidis, Saskia Litière, K Aalders, H. Wildiers, Peter Vuylsteke, Giuseppe Curigliano
Publikováno v:
Cancer Research. 78:PD3-09
Introduction: Pertuzumab (P) is approved as first line therapy for HER2-positive (HER2+) metastatic breast cancer (MBC) combined with trastuzumab (T) and docetaxel. However older patients are at higher risk of chemotherapy-induced toxicity raising hi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ef12c1176cbf5ccc48c27a2a9c5033ae
https://doi.org/10.1158/1538-7445.sabcs17-pd3-09
https://doi.org/10.1158/1538-7445.sabcs17-pd3-09
Autor:
B. Linderholm, John W.M. Martens, Joanna Vermeij, M Nowaczyk, Oliver Bogler, Sharon H. Giordano, Melissa Murray, C. Poncet, Kevin Punie, Cecilia Nilsson, Carolien P. Schröder, John M. S. Bartlett, Ingrid Hedenfalk, Lavinia P. Middleton, K Aalders, Fatima Cardoso, Kathryn J. Ruddy, Stefan Aebi, Isabel T. Rubio, E van Leeuwen-Stok, Theodora Goulioti, Peggy L. Porter, Aleksandra Peric, Catherine M. Kelly, Judith Fraser, C. J. van Asperen, Kim Benstead, L. Dal Lago, Leen Slaets, Eric P. Winer, Konstantinos Tryfonidis, Jane Bayani, Saskia Litière, Larissa A. Korde, Clifford A. Hudis, C.H.M. van Deurzen
Publikováno v:
Annals of Oncology, 29(2), 405-417
Annals of Oncology, 29(2), 405-417. Oxford University Press
Annals of Oncology, 29(2), 405-417. Elsevier Ltd.
Annals of Oncology
Annals of Oncology, 29(2), 405-417. Oxford University Press
Annals of Oncology, 29(2), 405-417. Elsevier Ltd.
Annals of Oncology
Background: Male breast cancer (BC) is rare, managed by extrapolation from female BC. The International Male BC Program aims to better characterize and manage this disease. We report the results of part I, a retrospective joint analysis of cases diag
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7a058eb6a13d166c7b0895e8f1f48963
https://hdl.handle.net/1887/79616
https://hdl.handle.net/1887/79616
Autor:
A.Moreno Aspitia, D.Agbor Tarh, Amylou C. Dueck, M.J. Piccart, Olena Werner, L. Dal Lago, Larissa A. Korde, Christos Sotiriou, Florentine Hilbers, Noam Pondé, E. de Azambuja, R. D. Gelber, Aminah Jatoi, C. Jackisch
Publikováno v:
Journal of Geriatric Oncology. 10:S14-S15
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::897ef3e1014f95de21d02bdf4152d0a3
https://doi.org/10.1016/s1879-4068(19)31143-9
https://doi.org/10.1016/s1879-4068(19)31143-9
Autor:
A. Piron, Cindy Kenis, D. Bron, T. Lamy de la Chapelle, Vincent Thibaud, L. Dal Lago, Michel Delforge, Cindy Borghgraef, T. Pepersack, H. Wilders
Publikováno v:
Journal of Geriatric Oncology. 10:S106
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e5864e335bbb7f0af6c06fa1b699d926
https://doi.org/10.1016/s1879-4068(19)31296-2
https://doi.org/10.1016/s1879-4068(19)31296-2
Autor:
Hannelore Denys, Noam Pondé, E. de Azambuja, L. Decoster, Hans Wildiers, L. Dal Lago, Peter Vuylsteke, Patrick Neven, G. Jerusalem, Cindy Kenis, François Duhoux
Publikováno v:
Annals of Oncology. 30:v140
Background Ribociclib in combination with endocrine therapy (ET) is the current standard of care in first-line for HR+/HER2- aBC. An increasing proportion of patients who are candidates for ribociclib are older (≥70 years of age). The number of old
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6668c4388cb622c3fe7249fc23c23eb0
https://doi.org/10.1093/annonc/mdz242.080
https://doi.org/10.1093/annonc/mdz242.080
Autor:
D. Bron, Vincent Thibaud, T. Lamy de la Chapelle, Michel Delforge, L. Dal Lago, T. Pepersack, L. Deneve, Stéphanie Dubruille, H. Wildiers, Cindy Kenis, Cindy Borghgraef
Publikováno v:
HemaSphere. 3:699
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b9d0a0cf12cd41310ac827cddab4f17a
https://doi.org/10.1097/01.hs9.0000564328.87522.a2
https://doi.org/10.1097/01.hs9.0000564328.87522.a2